Integrative Network Pharmacology and Experimental Validation Reveal Multi-target Hepatoprotective Mechanisms of Bioactive Compounds from Xiao-Yao-San
Iranian Journal of Pharmaceutical Research · 03.06.2026 · 25 (1)
DOI: 10.5812/ijpr-171015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 03.06.2026. Verfasst von Zi-Yi Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Xiao-Yao-San (XYS), a classical Traditional Chinese Medicine formula documented in the Chinese Pharmacopoeia, has long been used to treat hepatic disorders; however, its multi-target hepatoprotective mechanisms remain systematically uncharacterized.
Objectives
This study aimed to elucidate the hepatoprotective mechanisms of XYS bioactive compounds against drug-induced liver injury (DILI) using an integrative network pharmacology and experimental approach.
Methods
Network pharmacology was integrated with transcriptomic analysis and machine learning to identify hub targets. Molecular docking was used to predict interaction patterns and relative binding energies between compounds and target proteins. Hepatoprotective effects were validated in an acetaminophen (APAP)-induced hepatotoxicity model in HepG2 cells by measuring cytotoxicity markers and hub gene expression.
Results
Network pharmacology identified 125 bioactive compounds with 121 targets overlapping DILI pathogenesis. Machine learning identified five hub genes: ALOX5, CYP1A2, CYP3A4, F3, and PDE5A. Molecular docking showed favorable binding affinities (-5.02 to -8.66 kcal/mol) for four compounds: Beta-sitosterol, kaempferol, luteolin, and quercetin. All four compounds attenuated APAP-induced hepatotoxicity and modulated hub gene expression, with beta-sitosterol showing the most comprehensive hepatoprotective profile.
Conclusions
The bioactive compounds of XYS may contribute to hepatoprotection against DILI through multi-target regulation involving the ALOX5-LTB4 inflammatory axis, CYP-mediated metabolic regulation, F3-associated procoagulant signaling, and PDE5A/cGMP-related signaling.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
- College of Life Sciences, Nanjing Normal University, Nanjing, China.
- Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
- College of Agriculture and Biotechnology, Lishui University, Lishui, China.
ORCID-Profile: Zi-Yi Zheng, Jing-Yi Chen, Roy You Chen Quah, Guo-Hua Ding, Jing Chen
Zitieren
APA
Zheng, Z. Y., Chen, J. Y., Quah, R. Y. C., Ding, G. H., & Chen, J. (2026). Integrative Network Pharmacology and Experimental Validation Reveal Multi-target Hepatoprotective Mechanisms of Bioactive Compounds from Xiao-Yao-San. Iranian Journal of Pharmaceutical Research, 25(1). https://doi.org/10.5812/ijpr-171015
Vancouver
Zheng ZY, Chen JY, Quah RYC, Ding GH, Chen J. Integrative Network Pharmacology and Experimental Validation Reveal Multi-target Hepatoprotective Mechanisms of Bioactive Compounds from Xiao-Yao-San. Iranian Journal of Pharmaceutical Research. 2026;25(1). doi:10.5812/ijpr-171015
BibTeX
@article{Zheng2026,
author = {Zheng, Zi-Yi and Chen, Jing-Yi and Quah, Roy You Chen and Ding, Guo-Hua and Chen, Jing},
title = {Integrative Network Pharmacology and Experimental Validation Reveal Multi-target Hepatoprotective Mechanisms of Bioactive Compounds from Xiao-Yao-San},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2026},
volume = {25},
number = {1},
doi = {10.5812/ijpr-171015}
}
EUVIMED